Newsroom

A study led by Drs. Emma Puighermanal and Albert Quintana, and published in the journal Nature Communications, demonstrates in animal models how daily administration of cannabidiol (CBD) extends lifespan and improves symptoms associated with Leigh syndrome. The research group also demonstrated in both mice and fibroblasts from children with the disease that CBD improves cellular function.

The Best Global Universities Rankings, published by US News, places the UAB in the 1st position of the Spanish universities doing research in Neurosciences and the #49 in the world.

The Translational Mechanisms of Fear Memory Lab described in an article published in Science Advances the detection of new neuronal circuits involved in fear memory that differ in males and females. These findings have profound implications in understanding human neuropsychiatric disorders, such as post-traumatic stress disorder (PTSD), which exhibit fear memory alterations.

A study coordinated by Dr Xavier Navarro demonstrates in animal models how EGNITE, a derivative of graphene, allows the creation of smaller electrodes, which can interact more selectively with the nerves they stimulate, thus improving the efficacy of the prostheses.

The Anoche tuve un sueño magazine awarded Dr. Albert Quintana for his project to create a kit to detect antibiotic resistance.

The Neurodocs Student Association organized a calçotada last April 6, which brought together around 30 members of the Institute.

The Institute has signed a collaboration agreement with AdSalutem, a reference center in sleep medicine and brain health. The idea of ¿¿the agreement is to promote collaborations between INc-UAB groups and professionals from the centre.

Researchers at the Institute have carried out two revealing studies on TRPV2, a key ion channel in several cellular functions, which points to it as a possible new therapeutic target in the treatment of hypertension. On the one hand, they have discovered the vessel-dilating effects of its activation and, on the other, they have identified a molecule capable of activating it in a more potent way than the drugs known to date.

A research team led by Dr Esther Dalfó has managed to generate and validate a new animal model.  This model enables the examination of the initial phases of Parkinson's disease, occurring prior to the onset of motor symptoms, and the exploration of molecular processes preceding neuronal degeneration. The new model, based on the Caenorhabditis elegans worm, emerges as an essential tool in creating future therapies aimed at stopping the characteristic loss of neuronal structure and function seen in the disease.

A study coordinated by Dr. Jiménez-Altayó demonstrates in animal models the benefits of vorinostat after having suffered a stroke. The drug, used in humans to treat cutaneous T-cell lymphoma, has been proved to mitigate brain injuries and help in restoring brain tissue.